Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07663864 Luspatercept-AAMT Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07663864 clinical trial report covering Luspatercept-AAMT, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07662681 Famitinib Malate Salivary gland carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07662681 clinical trial report covering Famitinib Malate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07662720 Axelopran Cancer Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07662720 clinical trial report covering Axelopran, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07662174 Sirolimus Cerebral Hemorrhage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07662174 clinical trial report covering Sirolimus, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07666815 Creatine monohydrate Chronic Kidney Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07666815 clinical trial report covering Creatine monohydrate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07665970 SCTB39G Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665970 clinical trial report covering SCTB39G, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664150 CAN016 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664150 clinical trial report covering CAN016, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07665684 Albumin-Bound Paclitaxel Mucinous Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665684 clinical trial report covering Albumin-Bound Paclitaxel, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07665996 Girocitinib Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07665996 clinical trial report covering Girocitinib, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07664696 Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs) COVID-19 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07664696 clinical trial report covering Isolated, placental, mesenchymal stem cell exosomes(Kimera Labs), Phase 1/2, endpoints, sponsor, geography, read
Latest Hotspot
8 min read
NCT07668960 BBM-C101 Squamous Intraepithelial Lesions of the Cervix Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668960 clinical trial report covering BBM-C101, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07668284 Ubidecarenone Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07668284 clinical trial report covering Ubidecarenone, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.